Nuvation Bio Inc (NYSE: NUVB) shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422.
Gainers
Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.